# Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE

> **NIH NIH P50** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2022 · $664,838

## Abstract

PROJECT SUMMARY/ABSTRACT
Through this application, The University of Texas MD Anderson Cancer Center seeks funding for renewal of
its Prostate Cancer SPORE. This application is submitted under the Multiple Principal Investigator plan (MPI)
by Principal Investigators Drs. Christopher J. Logothetis and Timothy C. Thompson, who are recognized
internationally for their research in prostate cancer, The MD Anderson Prostate Cancer SPORE has created a
stable and dynamic infrastructure for translational research to meet and successfully address specific
challenges in reducing suffering and mortality rates for men with prostate cancer. We continue to build on our
capacity to conduct novel, innovative clinical trials and believe that new research projects conducted by our
translational research team will yield substantial progress and meaningful changes in clinical practice. In the
current proposal, we define our translational research challenges and goals as (1) quantitative definition of
prostate cancer risk to eliminate overtreatment of low-risk prostate cancer, (2) development of novel
therapeutic approaches to overcoming resistance of castration-resistant prostate cancer (CRPC) to available
therapies, and (3) development of novel alternative strategies for CRPC and treatment-refractory disease. We
will achieve these translational research goals by identifying and testing novel predictive and prognostic
biomarkers to determine the need for therapy in patients with early-stage prostate cancer, developing and
testing novel immunotherapy for CRPC, developing and testing a novel approach to overcoming osteocrine-
mediated resistance of bone metastasis to therapy, and developing and testing lead-in combination therapy to
maximize DNA damage response-targeted therapy for CRPC. We will accomplish our goals via 4 research
projects (including one population science research project), 3 support cores (Administrative, Biostatistics and
Bioinformatics, and Biospecimen and Pathology), a dynamic Developmental Research Program, and an
effective Career Enhancement Program. We are optimistic that our research efforts will contribute to
reductions in the incidence, morbidity, and mortality of this devastating disease by translating basic research
findings into clinical practice.

## Key facts

- **NIH application ID:** 10704453
- **Project number:** 3P50CA140388-10S1
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** Christopher J. Logothetis
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $664,838
- **Award type:** 3
- **Project period:** 2009-09-02 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10704453

## Citation

> US National Institutes of Health, RePORTER application 10704453, Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE (3P50CA140388-10S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10704453. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*